Abstract. Envenomation by Loxosceles species (brown spider) can lead to local dermonecrosis and to serious systemic effects. The main toxic component in the venom of these spiders is sphingomyelinase D (SMase D) and various isoforms of this toxin are present in Loxosceles venoms. We have produced a new anti-loxoscelic serum by immunizing horses with recombinant SMase D. In the present study, we compared the neutralization efficacy of the new antiloxoscelic serum and anti-arachnidic serum (the latter serum is used for therapy for loxoscelism in Brazil) against the toxic effects of venoms from spiders of the genus Loxosceles. Neutralization tests showed that anti-SMase D serum has a higher activity against toxic effects of L. intermedia and L. laeta venoms and similar or slightly weaker activity against toxic effects of L. gaucho than that of Arachnidic serum. These results demonstrate that recombinant SMase D can replace venom for anti-venom production and therapy.
INTRODUCTION
Envenomation by Loxosceles spp. spiders is a public health problem in Brazil, and loxoscelism is considered the most dangerous form of araneism in this country. Systemic reactions, including shock, hemolysis, renal insufficiency, and disseminated intravascular coagulation, are rare. In contrast, bite reactions ranging from small areas of erythema to large areas of ulceration and necrosis are frequently observed. 1 The bite is relatively painless and patients often are unaware that they have been bitten. Mild to severe pain, beginning 2-8 hours after envenomation, is probably caused by ischemia. Erythema with itching, swelling, and mild to severe tenderness is also observed. At this point, the patient might consult a physician. 1 At least three Loxosceles species of medical importance are known in Brazil (L. intermedia, L. gaucho, and L. laeta) and more than 3,000 cases of envenomation by L. intermedia are reported each year. In North America, several Loxosceles species, including L. reclusa (brown recluse), L. apachea, L. arizonica, L. unicolor, L. deserta, and L. bonetti, are the principal cause of numerous incidents of envenomation. [2] [3] [4] [5] In South Africa, L. parrami and L. spinulosa are responsible for cutaneous loxoscelism 6 and in Australia, a cosmopolitan species, L. rufescens, is capable of causing ulceration in humans.
A variety of treatments such as systemic steroids, antivenom, phentolamine, heparin, chloroprofenpyridamine maleate, dapsone, hyperbaric oxygen, and other substances have been used for therapy, with little or no benefit and, in some cases, with undesirable collateral effects. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] Most treatments have attempted to reduce infiltration of polymorphonuclear (PMN) leukocytes, the hallmark of cutaneous loxoscelism. PMN leukocyte infiltration, in part recruited by indirect activation of the complement system, is a major contributor to tissue damage. [21] [22] [23] [24] [25] Treatments to reduce PMN leukocyte infiltration are fraught with side effects and, in some cases, can increase tissue injury. 22 In Brazil, serum therapy combined with corticosteroids constitute the most common intervention for loxoscelism, and the Brazilian Ministry of Health recommends its use in moderate and severe cases with systemic illness and to reduce severity of the reaction and healing time. 26 The antiserum most commonly used for treatment of loxoscelism in Brazil is anti-arachnidic serum. This serum is produced by the Instituto Butantan (São Paulo, Brazil) by hyperimmunization of horses with venoms of the spiders L. gaucho and Phoneutria nigriventer and the scorpion Tityus serrulatus. Several studies have indicated that sphingomyelinase D (SMase D) in venom of Loxosceles spp. spiders is the main component responsible for local and systemic effects observed in loxoscelism. 25, [27] [28] [29] [30] [31] [32] [33] [34] [35] The difficulty in obtaining large amounts of venom and purified venom components is one of the limiting factors in studying the mechanisms involved in loxoscelism and raising an effective therapeutic antiserum. We have recently cloned and expressed one of the sphingomyelinases from L. laeta venom (SMase I), which displayed all biological activities endowed by whole venom. 35 An antiserum raised in rabbits against this recombinant protein effectively neutralized L. laeta venom toxicity. We have also cloned and expressed two functional isoforms of SMase (P1 and P2) from L. intermedia and shown that the recombinant proteins display all functional characteristics of whole venom, e.g., dermonecrotic and complement-dependent hemolytic activities and ability to hydrolyze sphingomyelin (SM). We have also compared the cross-reactivities of antisera raised in rabbits against SMase D from different Loxosceles species and showed that the crossreactivity is high when toxins are from the same species but lower when the toxins are from different species (L. intermedia versus L. laeta). 32 These data suggest that to obtain a suitable neutralizing antiserum using recombinant SMase D as immunogen, a mixture of the recombinant toxins from the different species is a requirement. On the basis of these data, we have developed a new anti-loxoscelic serum by horse immunization with a mixture of recombinant sphingomyelinases (P1, P2, and SMase 36 with slight modifications. Briefly, 15-20V electrical stimuli were repeatedly applied to the spider sternum and the venom drops were collected with a micropipette, vacuum dried, and stored at −20°C. Stock solutions were prepared in PBS at a concentration of 1.0 mg/mL. The protein content of the samples was evaluated by the method of Smith and others 37 by using the BCA Protein Assay kit (Pierce Biotechnology, Woburn, MA).
Expression of recombinant protein. Production of recombinant mature SMases I from L. laeta (accession no. AY093599) and P1 and P2 from L. intermedia (accession nos. AY304471 and AY304472, respectively) was performed as described. 32, 35 Antisera. Commercial anti-arachnidic serum (batch no 0506118), produced by immunizing horses with a mixture of venoms from L. gaucho (21.5%), P. nigriventer (21.5%), and T. serrulatus (57%) and experimental anti-SMase D serum, produced by immunizing horses with a mixture of recombinant SMases D from Loxosceles spp. spiders (P1 and P2 from L. intermedia 32 and SMase I from L. laeta 35 ), were obtained from the BioIndustrial Division, Instituto Butantan. Production and purification of anti-SMase D serum are patented processes (patent no. 0404765-6, INPI). Normal horse serum was obtained from non-immunized animals.
Normal human serum and erythrocytes. Human blood was obtained from healthy donors. Blood samples used for serum were collected without anticoagulant and allowed to clot for two hours at room temperature; normal human serum was stored at −80°C. Blood samples used for obtaining erythrocytes for subsequent use as target cells were collected in Alsever's old solution.
Electrophoresis and Western blotting. Samples of venoms and recombinant proteins were solubilized in reducing sample buffer and subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) on 12% polyacrylamide gels 38 and silver staining. Alternatively, gels were blotted onto nitrocellulose membranes. 39 After transfer, membranes were blocked with PBS containing 5% BSA and incubated with anti-arachnidic or anti-SMase D horse sera (diluted 1:2,000) for one hour at room temperature. Membranes were washed three times (10 minutes/wash) with PBS/ 0.05% Tween 20 and incubated with goat anti-horse IgG labeled with AP (diluted 1:3,000) in PBS/1% BSA for one hour at room temperature. The membranes were then washed three times (10 minutes/wash) with PBS/0.05% Tween 20 and blots were developed using NBT/BCIP according to the manufacturer's instructions (Promega).
Enzyme-linked immunosorbent assay (ELISA). Microtiter plates were coated with 100 L of Loxosceles spp. venom or recombinant proteins (10 g/mL) overnight at 4°C. Plates were blocked with 5% BSA in PBS and dilutions of antiarachnidic or anti-SMase D horse sera in PBS were added. After incubation for one hour at room temperature, plates were washed with PBS/0.1% Tween 20 and incubated with goat anti-human IgG labeled with HRP (diluted 1:1,000) for one hour at room temperature. Plates were washed and developed with o-phenylenediamine dihydrochloride (OPD) substrate according to the manufacturer's (Sigma) recommendations. Alternatively, titers of IgG T from anti-arachnidic and anti-SMase D horse sera were determined by coating microtiter plates with 100 L of goat anti-horse IgG against horse IgG T (250 g/mL) overnight at 4°C. Plates were blocked with 5% BSA in PBS and dilutions of anti-arachnidic and anti-SMase D sera made in PBS were added. After incubation for one hour at room temperature, plates were washed with PBS/0.1% Tween 20 and incubated with goat anti-horse IgG labeled with HRP RP (diluted 1:3,000) for one hour at room temperature. Plates were washed and developed with OPD substrate according to the manufacturer's (Sigma) recommendations. Titers were established as the highest antiserum dilution in which an absorbance was five times greater than that for normal serum.
Neutralization of dermonecrotic activity by sera. The ability of the anti-arachnidic and anti-SMase D sera to neutralize dermonecrotic activity was measured by an in vivo method. 40 Two hundred microliters of L. gaucho, L. intermedia, or L. laeta venoms in PBS (15 g/mL) were injected intradermally into shaved backs of adult rabbits. Simultaneously, 1 mL of normal or test sera was injected intravenously. The size of the lesions was measured over a period of 72 hours after injection. Neutralization was expressed as percentage reduction in size of the dermonecrotic lesion and calculated using as reference the extent of lesions developed by animals injected with the venoms and treated with normal serum.
Neutralization of hemolytic activity by sera. The ability of the anti-arachnidic and anti-SMase D sera to block hemolytic activity induced by Loxosceles spp. venoms was assessed by analyzing inhibition of GPC cleavage on the erythrocyte cell membrane as described. 30 ). Background or total cell lysis was evaluated by incubation of erythrocytes with VBS ++ or water, respectively. After incubation for one hour at 37°C, unlysed cells were centrifuged and the absorbance of the supernatant was measured at 414 nm and expressed as percentage of lysis. Because high concentrations of serum were used in the assays, the absorbance of serum without erythrocytes was subtracted from all samples. Percentage lysis was calculated as (absorbance sample − absorbance serum )/ (absorbance water − absorbance VBS++ ) × 100. Mean and standard deviations were determined from duplicate samples. Erythrocytes and normal human serum were always obtained from the same donor.
Once the venom concentration to be used in the neutralization assays was determined (3 g/mL), 25 L of 2% human erythrocytes were incubated with Loxosceles spp. Neutralization of SMase activity by sera. The SMase D activity in Loxosceles spp. venoms was measured as described. 41 Briefly, samples containing increasing concentrations of the Loxosceles spp. venoms were incubated with 50 g of SM diluted in 1 mL of HBS for 20 minutes at 37°C. One unit/mL of choline oxidase, 0.06 units/mL of HRP, and 50 M of 3-(4-hydroxy-phenyl)propionic acid in HBS was added and incubated for 10 minutes. The choline liberated was oxidized to betaine and H 2 O 2 . The oxidation products were measured by fluorimetry at em ‫ס‬ 405 nm and ex ‫ס‬ 320 nm by using 96-well microtiter plates in a spectrofluorimeter (Victor 3™; Perkin-Elmer, Waltham, MA). Once the venom concentration used in neutralization assays (1 g) was determined, venom samples were incubated for 30 minutes at 37°C with increasing dilutions of normal, anti-arachnidic, or anti-SMase D sera. Samples were then centrifuged for 20 minutes at 10,000 × g and supernatants were analyzed for SMase D activity in the samples as described above.
Statistical analysis. Data were analyzed by using the Student's t-test. A P value < 0.05 was considered significant.
RESULTS
Immunochemical cross-reactivity and serum titers. Analysis of venoms from L. gaucho, L. laeta, and L. intermedia by SDS-PAGE and silver staining showed differences in composition, number and intensity of bands. However, all venoms contained components with molecular masses of 32-35 kD, which includes the main toxic components of Loxosceles spp. venoms, the SMases D (Figure 1) . Western blot analysis showed that anti-arachnidic serum recognized most of the components in venoms and that antibodies to SMase D identified only components with molecular masses of 32-35 kD in L. laeta and L. gaucho venom (Figure 1) . In L. intermedia venom, antibodies to SMase D reacted with 32-35-kD SMase D proteins and with proteins with molecular masses twice that of the 32-35-kD proteins, which may indicate the presence of SMase D dimers.
Cross-reactivities of the two sera were tested by ELISA using L. gaucho, L. intermedia, and L. laeta venoms as antigens. As shown in Figure 2A , both sera recognized all tested antigens. Although anti-arachnidic serum contained higher levels of antibodies against venom of L. gaucho than against L. intermedia and L. laeta venom, antibodies to SMase D contained the highest level of antibodies against L. intermedia venom. The antibody titer against L. gaucho was much lower in the anti-SMase D serum than that in the anti-arachnidic serum. Both antisera had the same antibody titer against L. laeta venom. Because horse IgG T is considered the most important antibody isotype in the neutralization of toxins, 42 the anti-arachnid and anti-SMase D sera were compared by ELISA for their contents of IgG T. Figure 2B shows that the anti-SMase D serum had much higher titers of IgG T than the anti-arachnidic serum.
Analysis of neutralization potential of anti-arachnidic and anti-SMase D sera. To determine whether toxins responsible for the main toxic effects of Loxosceles spp. venoms could be Neutralizing ability of the two antisera on Loxosceles spp. venom dermonecrotic activity was determined by an in vivo test. Loxosceles gaucho, L. intermedia, or L. laeta venoms were injected intradermally into the backs of adult rabbits and, simultaneously, antisera were injected intravenously. Size of the lesions was measured during a 72-hour after injection. Groups of animals were injected intradermally with venoms and intravenously with normal horse serum were used as controls. Figure 3B -D shows that anti-SMase D serum was more active than anti-arachnidic serum in neutralizing the dermonecrotic activity of L. intermedia and L. laeta (P < 0.05) venoms, and the neutralization activity of the two antisera for the L. gaucho venom was the same.
Inhibition of hemolytic activity of Loxosceles spp. venoms by sera. We previously showed that venoms/sphingomyelinases from L. intermedia, L. gaucho, and L. laeta spiders transform human erythrocytes into activators of the complement system. 28, 43 We subsequently elucidated the mechanism of complement susceptibility and showed that the toxins facilitate activation of the alternative pathway of complement on human erythrocytes by removal of GLPs as a consequence of activation of an endogenous metalloproteinase 30 and activation of the classic pathway of complement possibly by alteration of the membrane asymmetry with exposure of phosphatidylserine. 31, 44 Figure 4A shows that all Loxosceles spp. venoms tested induced autologous complement lysis of human erythrocytes in a dose-dependent manner. To determine if toxins responsible for induction of the removal of GPC and autologous complement hemolysis could be neutralized by the antisera, the venoms from Loxosceles spp. were mixed with human erythrocytes in the presence or absence of control serum or experimental sera. Figure 4B shows that anti-arachnidic serum was more efficient in neutralizing removal of GPC induced by L. gaucho venom than the anti-SMase D (P < 0.05). For L. intermedia venom and L. laeta venom, anti-SMas D serum ( Figure 4C and D) inhibited induction of removal of GPC more efficiently than anti-arachnidic serum (P < 0.05). Under the same experimental conditions, the control serum had no effect.
Inhibition of SMase activity of Loxosceles spp. venoms by sera. We previously showed that all local and systemic effects induced by whole Loxosceles spp. venoms were associated with the action of SMase D. [28] [29] [30] [31] [32] Figure 5A shows that all Loxosceles venoms hydrolyzed SM in a dose-dependent manner. To verify if antisera could inhibit the hydrolytic activity of sphingomyelinases, venoms were assayed for their ability to cleave SM in the presence or absence of control serum and experimental antisera. Figure 5B shows that the antiarachnidic serum was more efficient at neutralizing sphingomyelinase activity of L. gaucho venom than anti-SMase D at dilutions of 1:1 to 1:75 (P < 0.05). At the highest dilutions, both sera showed similar neutralization values. For L. intermedia venom, the anti-arachnidic serum was more efficient in neutralization than anti-SMase D at dilutions of 1:1 to 1:15 (P < 0.05). The two sera showed similar neutralization at dilutions of 1:30 to 1:75. At dilutions of 1:90 and 1:120 (P < 0.05) the anti-SMase D serum was more effective. For L. laeta, anti-SMase D serum was more efficient in neutralization than anti-arachnidic serum, mainly at the highest serum dilutions (Ն 1:30; P < 0.05). Under the same experimental conditions, the control serum was not able to inhibit the sphingomyelinase activity of the venoms.
DISCUSSION
Envenomation by Loxosceles spp. spiders is a welldocumented cause of necrotic skin lesions in humans. Although systemic loxoscelism is less common than the cutane- ous form, it is the main cause of death associated with Loxosceles spp. envenomation. Most deaths occur in children and are related to the South American species L. laeta. 1 Loxosceles spp. are the most poisonous spider in Brazil and more than 3,000 cases of envenomation by L. intermedia are reported each year. Sphingomyelinase D is the primary enzyme in Loxosceles spp. venom responsible for its major clinical effects in humans.
It is difficult to obtain large quantities of Loxosceles spp. venom. In addition, only venom from L. gaucho is used for the anti-arachnid serum and success of toxin neutralization by an antivenom depends on abundance of specific antibodies against the principal lethal toxin of the venom and its binding affinity for the toxin. 45, 46 Because we have recently cloned and expressed the main toxic components of L. intermedia and L. laeta (both considered to cause more severe pathologic effects than L. gaucho), we have produced a new antiloxoscelic serum by immunizing horses with a mixture of recombinant SMase D from venoms of L. intermedia and L. laeta, which are the main agents of loxoscelism in Brazil and South America, respectively. In the present study, we have analyzed the neutralization potential of this new antiloxoscelic serum against the toxic effects of venoms from spiders of the genus Loxosceles of medical importance in Brazil and compared it with the anti-arachnidic serum used for human therapy in this country.
Analysis of venoms from Loxosceles spp. by SDS-PAGE showed differences in composition, number, and intensity of bands. Western blotting demonstrated that although antiarachnidic serum was developed against venom from L. gaucho, this serum recognized most components in the three venoms. As expected, antibodies to SMase D recognized only components with molecular masses of 32-35 kD, which corresponded to SMase D in these venoms, although with less intensity than with these components in L. gaucho venom. In L. intermedia venom, antibodies to SMase D also reacted with some proteins with double the molecular of SMase D, which suggested the presence of SMase D dimers.
Results of ELISA also showed cross-reactivity of the antiarachnidic serum, but reactivity was highest within the same species. For antibodies to anti-SMase D, the highest titer was obtained against L. intermedia venom because in this horse serum preparation two SMases D, P1 and P2, were used in the immunization pool. Antibody titers against venoms in antiarachnidic serum and anti-SMase D serum indicate that antiarachnidic serum was raised against whole venom. Thus, antibody titers against active toxins (SMase D in venom) may be much lower; this result was confirmed by Western blotting (Figure 1) , which showed that anti-arachnidic serum recognizes not only SMase D but other proteins in venom.
We have shown that the amount of total IgG T, which is found in all antibodies to toxin, [47] [48] [49] [50] was higher in antibodies to SMase D. This result indicated a higher neutralization potential for this serum than for anti-arachnidic serum. To confirm this hypothesis, in vivo and in vivo-in vitro neutralization assays were performed. Results showed that, as previously suggested, 32, 35 the new anti-loxoscelic serum, which was raised against only the toxic component (SMase D), is able to control the toxic action of Loxosceles spp. venoms. Comparative analysis indicated that the anti-arachnidic serum, although able to neutralize heterologous venoms, such as those from L. intermedia and L. laeta, is less efficient than anti- SMas D. Conversely, for L. gaucho, anti-arachnidic serum, as expected, showed a better neutralization potential because its formulation venom was from L. gaucho and was used in the immunization pool.
In conclusion, using recombinant Loxosceles spp. toxins of the SMase D family, we have generated an effective antiLoxosceles serum with higher in vivo neutralizing capacity against L. intermedia and L. laeta venoms than the most widely used anti-arachnid antiserum. This development represents an important proof of the concept that recombinant SMases D can replace whole venom for anti-venom production and therapy. The fact that antibodies against a single toxin type are able to neutralize the major deleterious activities of a venom containing many other toxic components is not surprising because of the amount of SMase D in Loxosceles spp. venoms. A recent catalog of expressed sequence tags from L. laeta 51 showed large amounts of SMase D expressed in venom glands, representing 16% of all mRNAs and orders of magnitude higher than most other toxins. The remaining components may be important for other biological needs of the spider and may not play a role in the pathophysiologic effects of venom in humans.
If one considers that L. intermedia and L. laeta cause most cases of envenomation in Brazil and South America, respectively, antiserum used in therapy is effective against these venoms. Therefore, we recommend use of anti-SMase D serum. Local knowledge of the distribution of different Loxosceles spp. may also help in the choice of antiserum used. Inclusion of SMase D isoforms from L. gaucho venom in the immunization formulation to obtain a fully neutralizing horse antiserum against the three predominant Loxosceles spp. spiders that cause envenomation in Brazil would be beneficial.
